ResMed Inc. vs Advanced Drainage Systems Inc — how do they compare? ResMed Inc. trades at $225.92 (market cap $31.89B), while Advanced Drainage Systems Inc trades at $127.14 (market cap $9.52B). The key difference: ResMed Inc. is far larger — about 3.3× Advanced Drainage Systems Inc's market cap, and ResMed Inc. pays the higher dividend (1.16%). Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and Advanced Drainage Systems Inc for 43 Days on average.
| RMD | WMS | |
|---|---|---|
Market Cap | $31.89B | $9.52B |
Volume | 618,314 | 907,564 |
Sector | Health | Basic Materials |
52-Week High | $277.88 | $175.38 |
52-Week Low | $182.82 | $125.33 |
Typical Hold Time | 51 Days | 43 Days |
Enterprise Value | $31.24B | $11.12B |
Dividend Yield | 1.16% | 0.63% |
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $225.98, up 2.4% today, with a bullish technical signal and strong fundamentals. Revenue grew to $5.15B in 2025, with net income at $1.40B and a 26.94% net margin. Recent earnings beats and a 12-14% EPS growth outlook support momentum. The stock is near its pivot point of $227, with support at $225 and resistance at $228.
Outlook is positive with analyst consensus at Buy and a $242.70 price target. Risks include competitive pressures and ongoing legal investigations. Institutional buying and solid cash flow growth underpin the bullish case, though macroeconomic and regulatory factors warrant monitoring.
Advanced Drainage Systems (WMS) trades at $126.08, down 3.07% on the day, amid a bearish technical signal. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.49 exceeding expectations. Revenue for 2025 was $2.90 billion, with a net income margin of 15.5%. The company maintains strong profitability metrics, including a 24.9% ROE, and recently announced a quarterly dividend. Analyst consensus is mixed with a $188.70 price target, while institutional activity shows both new acquisitions and reductions in holdings.
WMS presents a balanced outlook with solid fundamentals and recent earnings beats offset by near-term technical weakness. Investment opportunities include sustained revenue growth and margin expansion from operational efficiencies. Key risks involve competitive pressures in the construction sector and potential volatility from macroeconomic factors. The stock's current valuation at a P/E of 21.48 offers a reasonable entry point relative to growth prospects, but investors should monitor cash flow trends given the projected net cash outflow in 2026.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →Advanced Drainage Systems Inc is engaged in designing, manufacturing, and marketing thermoplastic corrugated pipe and related water management products in North and South America, and Europe. The company's operating segment includes Pipe
Read more on WMS →